Posted by Michael Wonder on 28 Jan 2020
TLV is reviewing the subsidy of factor VIII drugs with side agreements
28 January 2020 - Factor VIII drugs are used to treat a form of hemorrhagic disease, hemophilia A, which involves impaired ability to form a sufficient amount of so-called coagulation factor VIII.
Patients are treated with drugs containing factor VIII concentrate.
In 2018, TLV completed a review of the subsidy for the thirteen Factor VIII drugs that were then included in the high-cost protection. In the context of the review, TLV, the regions and the pharmaceutical companies had tripartite consultations. These resulted in companies and regions signing side reimbursement agreements, which lowered drug costs for eleven of thirteen Factor VIII drugs. Following price reductions or through side agreements between regions and companies, twelve products remained in the drug benefits after completion of the review with general subsidy.
